BNP Molecular Forms and Processing by the Cardiac Serine Protease Corin

Advances in Clinical Chemistry

Volumn 61, Issue , 2013, Pages 1-31

  Ichiki, Tomoko ^a   Huntley, Brenda K ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

B type natriuretic peptide; Corin; Glycosylation; Heart failure; Processing

Indexed keywords

EID: 84878668631     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407680-8.00001-4     Document Type: Chapter

References (79)

1. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981, 28:89-94.
2. Yan W., Wu F., Morser J., Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8525-8529.
3. Sawada Y., Suda M., Yokoyama H., Kanda T., Sakamaki T., Tanaka S., et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J. Biol. Chem. 1997, 33:20545-20554.
4. Hawkridge A.M., Heublein D.M., Bergen H.R., Cataliotti A., Burnett J.C., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17442-17447.
5. Heublein D.M., Huntley B.K., Boerrigter G., Cataliotti A., Sandberg S.M., Redfield M.M., et al. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007, 49:1114-1119.
6. Liang F., O'Rear J., Schellenberger U., Tai L., Lasecki M., Schreiner G.F., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J. Am. Coll. Cardiol. 2007, 49:1071-1078.
7. McKie P.M., Cataliotti A., Lahr B.D., Martin F.L., Redfield M.M., Bailey K.R., et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J. Am. Coll. Cardiol. 2010, 55:2140-2147.
8. Lainchbury J.G., Troughton R.W., Strangman K.M., Frampton C.M., Pilbrow A., Yandle T.G., et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol. 2009, 55:53-60.
9. Yan W., Sheng N., Seto M., Morser J., Wu Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J. Biol. Chem. 1999, 274:14926-14935.
10. Lisy O., Redfield M.M., Schirger J.A., Burnett J.C. Atrial BNP endocrine function during chronic unloading of the normal canine heart. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R158-R162.
11. Lisy O., Redfield M.M., Jovanovic S., Jougasaki M., Jovanovic A., Leskinen H., et al. Mechanical unloading versus neurohumoral stimulation on myocardial structure and endocrine function in vivo. Circulation 2000, 102:338-343.
12. Ichiki T., Huntley B.K., Heublein D.M., Sandberg S.M., McKie P.M., Martin F.L., et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin. Chem. 2011, 57:40-47.
13. Semenov A.G., Tamm N.N., Seferian K.R., Postnikov A.B., Karpova N.S., Serebryanaya D.V., et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin. Chem. 2010, 56:1166-1176.
14. Brandt I., Lambeir A.M., Ketelslegers J.M., Vanderheyden M., Scharpe S., De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin. Chem. 2006, 52:82-87.
15. Boerrigter G., Costello-Boerrigter L.C., Harty G.J., Lapp H., Burnett J.C. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R897-R901.
16. Pankow K., Wang Y., Gembardt F., Krause E., Sun X., Krause G., et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ. Res. 2007, 101:875-882.
17. Boerrigter G., Costello-Boerrigter L.C., Harty G.J., Huntley B.K., Cataliotti A., Lapp H., et al. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1744-R1750.
18. Ralat L.A., Guo Q., Ren M., Funke T., Dickey D.M., Potter L.R., et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J. Biol. Chem. 2011, 286:4670-4679.
19. Toll L., Brandt S.R., Olsen C.M., Judd A.K., Almquist R.G. Isolation and characterization of a new atrial peptide-degrading enzyme from bovine kidney. Biochem. Biophys. Res. Commun. 1991, 175:886-893.
20. Muller D., Schulze C., Baumeister H., Buck F., Richter D. Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. Biochemistry 1992, 31:11138-11143.
21. Potter L.R. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011, 278:1808-1817.
22. Dickey D.M., Potter L.R. Human B-type natriuretic peptide is not degraded by meprin A. Biochem. Pharmacol. 2010, 80:1007-1011.
23. Dickey D.M., Potter L.R. ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency. Clin. Chem. 2011, 57:1272-1278.
24. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 2006, 27:47-72.
25. Garbers D.L., Chrisman T.D., Wiegn P., Katafuchi T., Albanesi J.P., Bielinski V., et al. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol. Metab. 2006, 17:251-258.
26. Huntley B.K., Ichiki T., Sangaralingham S.J., Chen H.H., Burnett J.C. B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J. Cell. Physiol. 2009, 225:251-255.
27. Pagel-Langenickel I., Buttgereit J., Bader M., Langenickel T.H. Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy. J. Mol. Med. (Berl.). 2007, 85:797-810.
28. Siriwardena M., Kleffmann T., Ruygrok P., Cameron V.A., Yandle T.G., Nicholls M.G., et al. B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation 2010, 122:255-264.
29. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002, 347:161-167.
30. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Llanos J., Santalo-Bel M., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J. 2006, 27:330-337.
31. Ordonez-Llanos J., Merce-Muntanola J. Natriuretic peptides: laboratory condiderations. Cardiac Markers in Clinical Practice 2010, 377-402. Jones and Bartlett Publications, Sudbury. J.L. Januzzi (Ed.).
32. Masson S., Latini R., Anand I.S., Vago T., Angelici L., Barlera S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin. Chem. 2006, 52:1528-1538.
33. Grantham J.A., Borgeson D.D., Burnett J.C. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am. J. Physiol. 1997, 272:R1077-R1083.
34. Marcus L.S., Hart D., Packer M., Yushak M., Medina N., Danziger R.S., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996, 94:3184-3189.
35. O'Connor C.M., Starling R.C., Hernandez A.F., Armstrong P.W., Dickstein K., Hasselblad V., et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 2011, 365:32-43.
36. Chen H.H., Grantham J.A., Schirger J.A., Jougasaki M., Redfield M.M., Burnett J.C. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J. Am. Coll. Cardiol. 2000, 36:1706-1712.
37. Chen H.H., Schirger J.A., Cataliotti A., Burnett J.C. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur. J. Heart Fail. 2006, 8:681-686.
38. Chen H.H., Glockner J.F., Schirger J.A., Cataliotti A., Redfield M.M., Burnett J.C. Novel protein therapeutics for systolic heart failure: chronic subcutaneous BNP. J. Am. Coll. Cardiol. 2012, 60:2305-2312.
39. Vanderheyden M., Bartunek J., Goethals M., Verstreken S., Lambeir A.M., De Meester I., et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin. Chem. Lab. Med. 2009, 47:248-252.
40. Miller W.L., Phelps M.A., Wood C.M., Schellenberger U., Van Le A., Perichon R., et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ. Heart Fail. 2011, 4:355-360.
41. Giuliani I., Rieunier F., Larue C., Delagneau J.F., Granier C., Pau B., et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin. Chem. 2006, 52:1054-1061.
42. Macheret F., Boerrigter G., McKie P.M., Costello-Boerrigter L.C., Lahr B.D., Heublein D.M., et al. Pro-B-type natriuretic peptide1-108 circulates in the general community: plasma determinants and detection of left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 2010, 57:1386-1395.
43. Miller W.L., Grill D.E., Jaffe A.S. Comparison of novel pro-BNP(1-108) and standard BNP assays in heart failure patients. Clin. Chim. Acta 2012, 413:920-926.
44. Dries D.L., Ky B., Wu A.H., Rame J.E., Putt M.E., Cappola T.P. Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ. Heart Fail. 2010, 3:220-227.
45. Niederkofler E.E., Kiernan U.A., O'Rear J., Menon S., Saghir S., Protter A.A., et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 2008, 1:258-264.
46. Seferian K.R., Tamm N.N., Semenov A.G., Mukharyamova K.S., Tolstaya A.A., Koshkina E.V., et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin. Chem. 2007, 53:866-873.
47. Wu C., Wu F., Pan J., Morser J., Wu Q. Furin-mediated processing of Pro-C-type natriuretic peptide. J. Biol. Chem. 2003, 278:25847-25852.
48. Jiang J., Wu S., Wang W., Chen S., Peng J., Zhang X., et al. Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J. Biol. Chem. 2011, 286:10066-10072.
49. Dries D.L., Victor R.G., Rame J.E., Cooper R.S., Wu X., Zhu X., et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005, 112:2403-2410.
50. Hooper J.D., Scarman A.L., Clarke B.E., Normyle J.F., Antalis T.M. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur. J. Biochem. 2000, 267:6931-6937.
51. Peng J., Jiang J., Wang W., Qi X., Sun X.L., Wu Q. Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes. Biochem. Biophys. Res. Commun. 2011, 411:593-598.
52. Knappe S., Wu F., Madlansacay M.R., Wu Q. Identification of domain structures in the propeptide of corin essential for the processing of proatrial natriuretic peptide. J. Biol. Chem. 2004, 279:34464-34471.
53. Langenickel T.H., Pagel I., Buttgereit J., Tenner K., Lindner M., Dietz R., et al. Rat corin gene: molecular cloning and reduced expression in experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1516-H1521.
54. Tran K.L., Lu X., Lei M., Feng Q., Wu Q. Upregulation of corin gene expression in hypertrophic cardiomyocytes and failing myocardium. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1625-H1631.
55. Calderone A., Bel-Hadj S., Drapeau J., El-Helou V., Gosselin H., Clement R., et al. Scar myofibroblasts of the infarcted rat heart express natriuretic peptides. J. Cell. Physiol. 2006, 207:165-173.
56. Jiang W., Cai D.Y., Pan C.S., Qi Y.F., Jiang H.F., Geng B., et al. Changes in production and metabolism of brain natriuretic peptide in rats with myocardial necrosis. Eur. J. Pharmacol. 2005, 507:153-162.
57. Chan J.C., Knudson O., Wu F., Morser J., Dole W.P., Wu Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:785-790.
58. Rame J.E., Drazner M.H., Post W., Peshock R., Lima J., Cooper R.S., et al. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. Hypertension 2007, 49:857-864.
59. Rame J.E., Tam S.W., McNamara D., Worcel M., Sabolinski M.L., Wu A.H., et al. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ. Heart Fail. 2009, 2:541-548.
60. Wang W., Liao X., Fukuda K., Knappe S., Wu F., Dries D.L., et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ. Res. 2008, 103:502-508.
61. Dong N., Chen S., Yang J., He L., Liu P., Zheng D., et al. Plasma soluble corin in patients with heart failure. Circ. Heart Fail. 2010, 3:207-211.
62. Shrestha K., Troughton R.W., Borowski A.G., Yandle T.G., Richards A.M., Klein A.L., et al. Plasma corin levels provide minimal prognostic utility incremental to natriuretic peptide in chronic systolic heart failure. J. Card. Fail. 2010, 16:621-627.
63. Ibebuogu U.N., Gladysheva I.P., Houng A.K., Reed G.L. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ. Heart Fail. 2011, 4:114-120.
64. Dong N., Chen S., Wang W., Zhou Y., Wu Q. Corin in clinical laboratory diagnostics. Clin. Chim. Acta 2012, 413:378-383.
65. Dong N., Dong J., Liu P., Xu L., Shi S., Wu Q. Effects of anticoagulants on human plasma soluble corin levels measured by ELISA. Clin. Chim. Acta 2010, 411:1998-2003.
66. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 2002, 40:976-982.
67. Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin. Chem. Lab. Med. 2002, 40:371-377.
68. Wang T.J., Larson M.G., Levy D., Leip E.P., Benjamin E.J., Wilson P.W., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol. 2002, 90:254-258.
69. Hogenhuis J., Voors A.A., Jaarsma T., Hillege H.L., Boomsma F., van Veldhuisen D.J. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur. J. Heart Fail. 2005, 7:81-86.
70. Durinx C., Neels H., Van der Auwera J.C., Naelaerts K., Scharpe S., De Meester I. Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin. Chem. Lab. Med. 2001, 39:155-159.
71. Chen S., Sen S., Young D., Wang W., Moravec C.S., Wu W. Protease corin expression and activity in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1687-H1692.
72. Peltonen T.O., Taskinen P., Soini Y., Rysa J., Ronkainen J., Ohtonen P., et al. Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis. Circulation 2007, 116:1283-1289.
73. Schellenberger U., O'Rear J., Guzzetta A., Jue R.A., Protter A.A., Pollitt N.S. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch. Biochem. Biophys. 2006, 451:160-166.
74. Semenov A.G., Postnikov A.B., Tamm N.N., Seferian K.R., Karpova N.S., Bloshchitsyna M.N., et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin. Chem. 2009, 55:489-498.
75. Jiang J., Pristera N., Wang W., Zhang X., Wu Q. Effect of sialylated O-glycans in pro-brain natriuretic peptide stability. Clin. Chem. 2010, 56:959-966.
76. Tonne J.M., Campbell J.M., Cataliotti A., Ohmine S., Thatava T., Sakuma T., et al. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin. Chem. 2011, 57:864-873.
77. Seferian K.R., Tamm N.N., Semenov A.G., Tolstaya A.A., Koshkina E.V., Krasnoselsky M.I., et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin. Chem. 2008, 54:866-873.
78. Nishikimi T., Ikeda M., Takeda Y., Ishimitsu T., Shibasaki I., Fukuda H., et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012, 98:152-161.
79. Lachmann R.H. Enzyme replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr. 2011, 23:588-593.